Juniper Pharmaceuticals

Juniper Pharmaceuticals is developing therapeutics that address unmet medical needs in women’s health. The Company's current pipeline leverages the 505(b)(2) regulatory pathway with new formulations of existing pharmaceuticals. Juniper's current intravaginal ring product candidates are JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women; JNP-0201, a combination estrogen + progesterone IVR for menopausal symptoms; and, JNP-0301, a progesterone IVR for the prevention of preterm birth in women with a short cervical length at mid-pregnancy.

Company Growth (employees)
Type
Public
HQ
Boston, US
Founded
1986
Size (employees)
139 (est)
Juniper Pharmaceuticals was founded in 1986 and is headquartered in Boston, US

Juniper Pharmaceuticals Office Locations

Juniper Pharmaceuticals has an office in Boston
Boston, US (HQ)
33 Arch St

Juniper Pharmaceuticals Data and Metrics

Juniper Pharmaceuticals Financial Metrics

Juniper Pharmaceuticals's revenue was reported to be $11.2 b in Q1, 2017
USD

Revenue (Q1, 2017)

11.2 b

Gross profit (Q1, 2017)

4.7 b

Gross profit margin (Q1, 2017), %

42%

Net income (Q1, 2017)

(1.4 b)

EBIT (Q1, 2017)

(1.5 b)

Market capitalization (17-Aug-2017)

49.3 m

Cash (31-Mar-2017)

21.8 m
Juniper Pharmaceuticals's current market capitalization is $49.3 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

29.2 m32.5 m37.6 m54.6 m

Revenue growth, %

11%16%45%

Cost of goods sold

13.3 m17.7 m21.4 m24.3 m

Gross profit

16 m14.8 m16.1 m30.3 m

Gross profit Margin, %

55%46%43%55%

Sales and marketing expense

1.3 m

R&D expense

9.7 m

General and administrative expense

14.1 m

Operating expense total

10.1 m11 m18.7 m25 m

EBIT

5.9 m3.8 m(2.5 m)5.3 m

EBIT margin, %

20%12%(7%)10%

Interest expense

(97 k)

Interest income

(97 k)

Pre tax profit

6.7 m4.4 m(2.1 m)6 m

Income tax expense

22.6 k988 k5 k91 k

Net Income

6.7 m3.4 m(2.1 m)6 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

6.9 m11.5 m8.3 m10.2 b11.5 b12.1 m11.9 m11.6 m11.2 b

Cost of goods sold

3.9 m5.1 m4.9 m5.6 b6.4 b6.4 m6.5 m5.7 m6.6 b

Gross profit

3 m6.4 m3.4 m4.6 b5 b5.8 m5.4 m5.9 m4.7 b

Gross profit Margin, %

44%56%41%45%44%48%46%51%42%

Sales and marketing expense

467 k467 k321 k282 m338 m272 k379 k259 k379 m

R&D expense

236 k1.4 m2.1 b1.6 b1.8 m3.6 m2.3 m1.3 b

General and administrative expense

2.2 m2.1 m2.6 m2.6 b2.2 b3.5 m3.2 m3.1 m4.4 b

Operating expense total

2.7 m2.9 m4.3 m5 b4.2 b5.5 m7.2 m5.7 m6.1 b

EBIT

282 k3.5 m(831 k)(333 m)869 m267 k(1.8 m)177 k(1.5 b)

EBIT margin, %

4%31%(10%)(3%)8%2%(15%)2%(13%)

Interest expense

(27 k)(27 m)(27 m)(26 k)(24 k)(24 k)(28 m)

Pre tax profit

359 k3.6 m(687 k)(323 m)956 m366 k(1.7 m)243 k(1.4 b)

Income tax expense

166 k(110 k)5 k3 m3 m4 k48 k(5 k)

Net Income

622 k4.3 m(692 k)(1 m)(65 k)362 k(1.7 m)248 k(1.4 b)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

20.7 m16.8 m13.9 m21 m

Accounts Receivable

7.2 m5.3 m181 k

Inventories

2.6 m3.2 m3.6 m5.6 m

Current Assets

32.2 m26.4 m26.7 m34.7 m

PP&E

13.2 m13 m12.9 m13.4 m

Goodwill

11.2 m10.5 m10 m8.3 m

Total Assets

60.1 m52.2 m51.4 m57.6 m

Accounts Payable

2.8 m2.9 m2 m3.9 m

Total Debt

500.3 k486 k476 k408 k

Current Liabilities

6.3 m5.9 m7.7 m15 m

Total Liabilities

17.3 m

Additional Paid-in Capital

287 m287.7 m289.5 m290.6 m

Retained Earnings

(241.7 m)(238.3 m)(240.4 m)(237.4 m)

Total Equity

46.9 m40.9 m39.4 m39.8 m

Debt to Equity Ratio

0 x0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x

Financial Leverage

1.3 x1.3 x1.3 x1.4 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

11.8 m16.4 m16.3 m16.1 m17.4 m13.5 m13 m15 m21.8 m

Accounts Receivable

7.2 m5.3 m4.8 m6.5 m7.9 m8 m6.2 m5.3 m4.5 m

Inventories

3.6 m2.9 m3.3 m3.8 m3.1 m3.2 m3.9 m4.8 m5.7 m

Current Assets

24 m25.8 m26.1 m28.6 m30.7 m27.5 m26.4 m26.4 m33.5 m

PP&E

14.2 m13.5 m12.3 m12.9 m12.8 m12.8 m12.2 m12.6 m13.8 m

Goodwill

11.5 m11 m10 m10.6 m10.3 m9.7 m9.1 m8.8 m8.4 m

Total Assets

53.2 m53.7 m50.5 m54.2 m55.7 m51.6 m49 m49 m56.8 m

Accounts Payable

3.1 m1.1 m2.5 m3 m3.4 m3.8 m3.8 m4.8 m2.7 m

Current Liabilities

6.8 m5.2 m5.8 m8.2 m9.5 m8.5 m9.4 m15.3 m14 m

Additional Paid-in Capital

287.4 m287.5 m288.2 m288.6 m289.1 m289.6 m289.9 m290.2 m291 m

Retained Earnings

(241 m)(237.4 m)(239 m)(239.3 m)(238.3 m)(240 m)(241.8 m)(247 m)(238.8 m)

Total Equity

40.1 m42.7 m39.7 m41.1 m41.7 m39.2 m36.3 m30.8 m38.9 m

Financial Leverage

1.3 x1.3 x1.3 x1.3 x1.3 x1.3 x1.4 x1.6 x1.5 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

6.7 m3.4 m(2.1 m)6 m

Depreciation and Amortization

919.1 k2 m1.9 m1.9 m

Accounts Receivable

(2.3 m)1.7 m(2.5 m)192 k

Inventories

46.5 k(619 k)(424 k)(2 m)

Accounts Payable

314.8 k91 k(925 k)1.6 m

Cash From Operating Activities

7.1 m6.9 m(891 k)11.2 m

Purchases of PP&E

(522.4 k)(2 m)(1.7 m)(3.6 m)

Cash From Investing Activities

315.1 k(2 m)(1.7 m)(3.6 m)

Short-term Borrowings

(72.3 k)(245 k)(238 k)(226 k)

Dividends Paid

(27.5 k)(28 k)(28 k)(28 k)

Cash From Financing Activities

(89.1 k)(8.7 m)(206 k)(254 k)

Interest Paid

24.9 k120 k101 k85 k

Income Taxes Paid

3 k3 k2 k2 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

622 k4.3 m(692 k)(1 m)(65 k)362 k(1.7 m)248 k(1.4 b)

Depreciation and Amortization

949 k1.5 m523 k1 m1.5 m

Accounts Receivable

149 k1.9 m353 k(1.1 m)(2.7 m)8 m6.2 m5.3 m4.5 m

Inventories

(966 k)(273 k)(130 k)(579 k)94 k3.2 m3.9 m4.8 m5.7 m

Accounts Payable

282 k(1.7 m)(343 k)(37 k)532 k3.8 m3.8 m4.8 m2.7 m

Cash From Operating Activities

869 k5.9 m(176 k)(38 k)2.1 m

Purchases of PP&E

(1.2 m)(1.5 m)(168 k)(525 k)(1.2 m)

Cash From Investing Activities

(1.2 m)(1.5 m)(168 k)(525 k)(1.2 m)

Short-term Borrowings

(121 k)(184 k)(59 k)(118 k)(179 k)

Dividends Paid

(14 k)(21 k)(7 k)(14 k)(21 k)

Cash From Financing Activities

(8.6 m)(8.7 m)(66 k)(49 k)(117 k)

Interest Paid

64 k93 k25 k51 k76 k

Income Taxes Paid

3 k3 k2 k2 k2 k
USDY, 2017

Revenue/Employee

80.9 m

Financial Leverage

1.5 x

Juniper Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

4

Juniper Pharmaceuticals Market Value History

Juniper Pharmaceuticals Job Categories

Traffic Overview of Juniper Pharmaceuticals

Juniper Pharmaceuticals Company Life and Culture

You may also be interested in